Prospective Assessment of Pediatrician-Diagnosed Food Protein-Induced Allergic Proctocolitis by Gross or Occult Blood

PEDIATRICS ◽  
2021 ◽  
Vol 148 (Supplement 3) ◽  
pp. S35-S35
Author(s):  
Shouling Zhang ◽  
Scott H. Sicherer
2020 ◽  
Vol 8 (5) ◽  
pp. 1692-1699.e1
Author(s):  
Victoria M. Martin ◽  
Yamini V. Virkud ◽  
Hannah Seay ◽  
Alanna Hickey ◽  
Renata Ndahayo ◽  
...  

2019 ◽  
Vol 143 (2) ◽  
pp. AB136 ◽  
Author(s):  
Victoria Martin ◽  
Yamini V. Virkud ◽  
Hannah L. Seay ◽  
Corinne Keet ◽  
Wayne G. Shreffler ◽  
...  

PEDIATRICS ◽  
2021 ◽  
Vol 148 (Supplement 3) ◽  
pp. S35-S36
Author(s):  
Monica T. Kraft ◽  
David Stukus

2021 ◽  
Vol 14 (4) ◽  
pp. e238743
Author(s):  
Kohichiroh Nii ◽  
Kaoru Okazaki ◽  
Hitoshi Okada ◽  
Toru Kuboi

Ulcerative colitis often develops in the reproductive age women and can cause exacerbation by pregnancy. Mesalazine (5-aminosalicylic acid) is recommended as a safe anti-inflammatory drug during pregnancy. However, maternal mesalazine is transferred to the fetus through the placenta and may cause allergic events. A pregnant woman with severe ulcerative colitis was treated with a dose of mesalazine 4,000 mg/day from early gestation to delivery. Immediately after birth, the preterm neonate vomited bloody contents and discharged massive gross haematochezia. Serum concentrations of mesalazine and its main metabolite were high in the mother and the umbilical cord. Faecal eosinophils and drug-induced lymphocyte stimulation test suggested possibility that sensitisation with mesalazine in utero caused allergic enterocolitis like food protein-induced allergic proctocolitis. Maternal mesalazine has a potential of fetal sensitisation and cause allergic disease.


PEDIATRICS ◽  
2021 ◽  
Vol 148 (Supplement 3) ◽  
pp. S37-S37
Author(s):  
Price Edwards ◽  
Anthony Olive ◽  
Carla M. Davis

2020 ◽  
Vol 145 (2) ◽  
pp. AB51
Author(s):  
Michael Marget ◽  
Victoria Martin ◽  
Yamini Virkud ◽  
Hannah Seay ◽  
Rachael Rosow ◽  
...  

2021 ◽  
Vol 26 (3) ◽  
pp. 173-176
Author(s):  
Elissa M Abrams ◽  
Kyla J Hildebrand ◽  
Edmond S Chan

Abstract The most common types of non-IgE-mediated food allergy are food protein-induced enterocolitis syndrome (FPIES) and food protein-induced allergic proctocolitis (FPIAP). FPIES presents with delayed refractory emesis, while FPIAP presents with hematochezia in otherwise healthy infants. Acute management of FPIES includes rehydration or ondansetron, or both. No acute management is required for FPIAP. Long-term management of both disorders includes avoidance of the trigger food. The prognosis for both conditions is a high rate of resolution within a few years’ time.


Antibiotics ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 1467
Author(s):  
Marie Heyne-Pietschmann ◽  
Dirk Lehnick ◽  
Johannes Spalinger ◽  
Franziska Righini-Grunder ◽  
Michael Buettcher ◽  
...  

The onset of bloody stools in neonates often results in antibiotic treatment for suspected necrotizing enterocolitis (NEC). Food protein-induced allergic proctocolitis (FPIAP) is an often-neglected differential diagnosis. We performed a retrospective analysis of antibiotic exposure at our tertiary center from 2011 to 2020 that included three time periods of differing antimicrobial stewardship goals. We compared these data with the conventional treatment guidelines (modified Bell’s criteria). In our cohort of 102 neonates with bloody stools, the length of antibiotic exposure was significantly reduced from a median of 4 to 2 days. The proportion of treated neonates decreased from 100% to 55% without an increase in negative outcomes. There were 434 antibiotic days. Following a management strategy according to modified Bell’s criteria would have led to at least 780 antibiotic days. The delayed initiation of antibiotic treatment was observed in 7 of 102 cases (6.9%). No proven NEC case was missed. Mortality was 3.9%. In conclusion, with FPIAP as a differential diagnosis of NEC, an observational management strategy in neonates with bloody stools that present in a good clinical condition seems to be justified. This may lead to a significant reduction of antibiotic exposure. Further prospective, randomized trials are needed to prove the safety of this observational approach.


Sign in / Sign up

Export Citation Format

Share Document